Publication Name	World Journal of Gastroenterology
Manuscript ID	116529
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Clinical Trials Study
Article Title	Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Yan Huang, Qing-Hua Zhong, Ying-Yi Kuang, Zhi-Jie Li, Bin-Jie Huang, Yan-Jiong He, Miao-Miao Zhu, Qi Guan, Xiao-Yan Li, Qi-Yuan Qin and Teng-Hui Ma
Funding Agency and Grant Number	Funding Agency Grant Number Clinical Research 1010 Program of the Sixth Affiliated Hospital of Sun Yat-sen University 1010CG(2022)-09 Guangdong Provincial Hospital Pharmaceutical Research Foundation 2021A07 Hospital Pharmaceutical Research Foundation of Guangdong Hospital Association YXKY202212 China International Medical Foundation Z-2021-46-2101-2023 Program of Guangdong Provincial Clinical Research Center for Digestive Diseases 2020B1111170004
Corresponding Author	Teng-Hui Ma, Department of Colorectal Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, No. 26 Yuancun Erheng Road, Guangzhou 510655, Guangdong Province, China. matengh@mail.sysu.edu.cn
Key Words	Bleeding; Chronic radiation proctitis; Thalidomide; Efficacy; Safety
Core Tip	Chronic radiation proctitis (CRP) is a common complication of pelvic radiotherapy. Its most frequent symptom is hematochezia, which is often persistent and irreversible. However, the availability of oral drug treatments for hemorrhagic CRP are still extremely limited. This single-arm, open-label, phase II clinical trial investigated the therapeutic efficacy and safety of thalidomide for refractory hemorrhagic CRP. The results demonstrated that thalidomide achieved a hematochezia remission rate of up to 83.9%, with only mild or moderate adverse events. In summary, thalidomide appears to be an effective and well-tolerated treatment option for hemorrhagic CRP.
Citation	Huang XY, Zhong QH, Kuang YY, Li ZJ, Huang BJ, He YJ, Zhu MM, Guan Q, Li XY, Qin QY, Ma TH. Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial. World J Gastroenterol 2026; In press

Received	2025-11-14 12:39
Peer-Review Started	2025-11-14 12:39
First Decision by Editorial Office Director	2025-12-05 09:35
Return for Revision	2025-12-05 09:35
Revised	2025-12-19 14:54
Publication Fee Transferred	2025-12-26 02:48
Second Decision by Editor	2026-02-02 02:59
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-02-03 04:08
Articles in Press	2026-02-03 04:08
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com